Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2019 Oct 17;28(1):57–67. doi: 10.1016/j.tim.2019.08.010

Influenza A Virus Hemagglutinin–Neuraminidase–Receptor Balance: Preserving Virus Motility

Erik de Vries 1,, Wenjuan Du 1, Hongbo Guo 1, Cornelis AM de Haan 1,
PMCID: PMC7172302  PMID: 31629602

Abstract

Influenza A viruses (IAVs) occasionally cross the species barrier and adapt to novel host species. This requires readjustment of the functional balance of the sialic acid receptor-binding hemagglutinin (HA) and the receptor-destroying neuraminidase (NA) to the sialoglycan-receptor repertoire of the new host. Novel techniques have revealed mechanistic details of this HA–NA–receptor balance, emphasizing a previously underappreciated crucial role for NA in driving the motility of receptor-associated IAV particles. Motility enables virion penetration of the sialylated mucus layer as well as attachment to, and uptake into, underlying epithelial cells. As IAVs are essentially irreversibly bound in the absence of NA activity, the fine-tuning of the HA–NA–receptor balance rather than the binding avidity of IAV particles per se is an important factor in determining host species tropism.

Keywords: influenza A virus, hemagglutinin, neuraminidase, sialic acid, receptor, mucus

Receptor Binding of Influenza A Virus

Influenza A viruses (IAVs) infect birds and mammals. Aquatic birds constitute the natural host reservoir of IAVs. Occasionally, these enveloped, negative-strand RNA viruses (Figure 1 ) cross the host species barrier and become established as viruses of humans or other mammals (e.g., porcine, equine, and canines). Their host tropism is determined by an interplay between different viral proteins and host factors that is crucial for efficient replication and transmission within a species. Host tropism switches require adaptation of IAV proteins to host factors of the novel host species. The IAV envelope carries trimeric hemagglutinin (HA) that binds to sialic acid (SIA) (see Glossary) receptors and its functional antagonist, the tetrameric receptor-destroying neuraminidase (NA) (Figures 1 and 2 ). Some 18 HA (H1–18) and 11 NA (N1–11) subtypes have been identified 1, 2. All combinations of H1–16 and N1–9 have been found in wild waterfowl IAVs [3]. Currently, H1N1 and H3N2 viruses are circulating in the human population. The question is not if, but when, a new animal IAV will manage to breach the host range barrier and cause the next influenza pandemic.

Figure 1.

Figure 1

Influenza A Virus (IAV) Particle

(A) Electron micrograph of negatively-stained A/Netherlands/602/2009 (H1N1) virus particle (picture kindly provided by Jan van Lent, Laboratory of Virology, Wageningen University and Research). The virion has a diameter of approximately 100 nm.

(B) Graphic representation of a generic IAV particle (Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases). Hemagglutinin (HA) trimers are shown in blue, neuraminidase (NA) tetramers in red, and M2 ion channels in purple. The lipid envelope has a brownish color. Virions display more HA trimers than NA tetramers. NA tetramers may be evenly distributed on the virion surface or be present in a patch-like distribution 88, 89, 128.

Figure 2.

Figure 2

Structure of Hemagglutinin (HA) and Neuraminidase (NA)

(A) Top view of an HA trimer (H3; PDB 6BKM, [129]) in a surface representation. The receptor-binding site is colored orange. The sialic acid (SIA) and galactose residues in the receptor-binding sites are shown in a stick representation colored purple and yellow, respectively.

(B) Top view of an NA tetramer (N2; PDB 4H53, [130]) in a surface representation. The SIA contact residues in the catalytic site and 2nd SIA-binding site (2SBS) in each protomer are colored red and blue, respectively. SIA residues in the 2SBS are shown in a stick representation (purple).

The receptor-binding properties of HA, a well-established host tropism determinant, need to change in order for an avian virus to evolve into a human virus. Avian viruses prefer binding to SIAs attached to cell-surface-associated glycan chains via an α2,3-linkage, while human viruses preferentially bind α2,6-linked SIAs 4, 5. A switch from α2,3 to α2,6 binding specificity requires several mutations in HA 6, 7, 8. However, the situation is a little more complex. HA proteins do not bind with similar affinity to every sialoside containing appropriately linked SIAs. Internal sugars and their linkages also affect the HA-receptor binding specificity 9, 10. Also, the α2,6/α2,3 dichotomy is not absolute. Several H1N1 11, 12 and H3N2 [13] human viruses have been reported to also bind avian-type α2,3 receptors, whereas avian IAVs of several genotypes bind to α2,6 receptors 14, 15, 16, 17, although none of the latter have (yet) breached the host range barrier. Once established as a human virus, the receptor binding properties further evolve with time, presumably in conjunction with antigenic drift [18] that predominantly occurs at positions surrounding the receptor-binding site 19, 20. As a consequence, successful human IAVs can acquire rather different HA binding properties 13, 21, 22. Considering the functional antagonism of HA and NA, it seems likely that not the receptor-binding properties of HA alone determine host tropism, but that the activities of HA and NA need to be well balanced in relation to the host receptor repertoire for optimal viral fitness. Novel developments with respect to this HA–NA–receptor balance are the main focus of this review (for previous reviews on this topic see 23, 24, 25, 26, 27).

HA–NA–Receptor Balance

We define the HA–NA balance as the balance between the activities of HA and NA on the full, highly diverse, spectrum of functional and decoy receptors present on cells and mucus. Multivalent IAV–receptor binding by low-affinity interactions of several HA trimers with sialosides 28, 29 enables a dynamic binding mode. Individual HA–SIA interactions (KD ∼1–20 mM) 30, 31 are rapidly formed and broken without causing dissociation of the virus but providing access of NA to temporarily free SIAs. Sialidase activity by NA results in reduced SIA-receptor density which drives virus movement, as first demonstrated by microscopy [32], and ultimately causes dissociation 33, 34. Functionally balanced HA and NA activities are traditionally considered to be important for efficient release of newly assembled virus particles 35, 36. They are also essential, however, in enabling virus penetration of the heavily sialylated mucus layer overlaying epithelial cells (Figure 3 ), and in supporting virus interactions with host cell receptors that result in endocytic uptake (Figure 4 ) as is described in more detail below.

Figure 3.

Figure 3

Influenza A Virus (IAV) Particles Penetrate the Mucus Layer of the Respiratory Tract

(A) IAV particles need to penetrate a gel-like mobile mucus layer as well as a brush-like periciliary layer to reach the underlying epithelial cells. The gel-like mobile mucus layer contains soluble mucins MUC5AC/5B, while the periciliary layer is occupied by membrane-spanning mucins and large mucopolysaccharides that are tethered to cilia, microvilli, and the epithelial cell surface [108]. Ciliated and nonciliated cells are shown, as well as mucus-producing goblet cells.

(B) Upon association of IAV particles with the mucus layer, they are continuously in a receptor-bound state. In the presence of mucus, inhibition of neuraminidase (NA) activity inhibits infection in vitro43, 94, 95, 96. The dynamics of IAV–receptor interactions allow the particles to move through the mucus layer in an NA-dependent manner 60, 97. We speculate that virions are rolling over heavily sialylated, elongated mucin molecules until they reach the sialylated glycocalyx of the epithelial cells.

Figure 4.

Figure 4

Dynamics of Influenza A Virus (IAV)–Receptor Interactions at the Mucus–Cell Interface

IAV particles are dynamically interacting with sialic acid (SIA) receptors present on O-glycans (present in high density on mucins) and on N-glycans (particularly present on the cell surface). Low-affinity hemagglutinin (HA)–SIA interactions 30, 31 are rapidly formed and broken, thereby allowing neuraminidase (NA) access to these receptors. Upon local receptor destruction resulting from SIA cleavage, virions move to a higher receptor density-containing vicinity. This NA-dependent movement likely occurs in the mucus layer 60, 97, but possibly also on the cell surface [32]. Binding of IAV particles to sialylated cell-surface receptors results in their (transient) clustering and activation, thereby inducing signaling events that trigger the uptake of IAV particles via receptor-mediated endocytosis 110, 111, 112.

The HA–NA balance is likely tuned to the receptor repertoire IAV encounters in a specific host species. Cells expose a dense layer of sialylated glycans attached to proteins and lipids (Figure 3). Whether binding to specific sialoglycoproteins or -lipids is required for endocytic uptake and infection is not known. IAVs appear to preferentially bind to N-linked glycans on proteins [37], but these are not absolutely essential for host cell entry in vitro [38]. Functional receptors that are required for cell entry may be restricted to specific sialoglycan chains, as well as the proteins or lipids to which they are attached. For example, the voltage-dependent Ca2+ channel Cav1.2 was proposed as an IAV entry receptor [39]. IAV entry was inhibited by Ca2+ channel blockers; however, knockdown of Cav1.2 decreased the number of IAV-infected cells only twofold. Other specific membrane proteins of which the specific sialylation state affected IAV entry have been described, including fibronectin [40] and platelet-derived growth factor (PDGF)-β [41]. It can also not be excluded that cells present decoy receptors that will have a negative effect on endocytic uptake, although no such molecules have been described so far. The sialoside-rich mucus layer definitely acts as a decoy for IAV. The soluble mucins herein are elongated proteins (longer than 100 nm with an average radius of gyration of ∼150 nm) [42], densely covered with short O-glycans forming a gel-like barrier to diverse pathogens (Figure 3; reviewed in [43]). Mucus also contains large numbers of potentially sialylated exosomes that may function as a decoy [44]. Thus, the sialoglycan repertoire of a host has a complex constitution and distribution of decoy and functional receptors. It varies between species 45, 46, 47, 48, and therefore a species-specific HA–NA balance is potentially restricting crossing of the species barrier by IAV.

The restoration of a functional HA–NA–receptor balance by the selection of mutations in either HA or NA in response to an inhibitory decoy receptor was first shown 36 years ago [49]. Since then the reassortment of HA and NA genome segments from different viruses has frequently been shown to attenuate the resulting viruses. Acquisition of mutations in HA or NA after reassortment 50, 51, or upon an otherwise disturbed balance 52, 53, 54, 55, has been shown to restore fitness, and the requirement of a functional HA–NA–receptor balance is widely accepted now (reviewed in 23, 24, 25, 26, 27). At the molecular level this HA–NA–receptor balance is, however, not well established. This is in part due to a biased focus on HA, but mainly because suitable assays for directly assessing the dynamics of virion–receptor interactions in the presence of NA activity are lacking. Studies using recombinant HA and NA proteins and monovalently displayed substrates are informative, but HA binding and NA sialidase activity inevitably occur at the multivalent configuration encountered at the virus–cell interface. Receptor-binding and sialidase-activity properties should therefore also be studied in the context of virus particles. Recently developed assays using biolayer interferometry (BLI) 33, 56, 57, 58, or fluorescence imaging microscopy 32, 59, allowed direct analysis of the dynamics of virus–receptor interactions. Initial interactions of virus particles with a receptor-coated surface are often short lived [59], presumably because they are driven by one or two HA–SIA binding events, each of which is rapidly formed and broken resulting from its very low affinity (KD ∼1–20 mM). However, the absence of NA activity also enabled virtually irreversible binding, as a result of multivalent HA–receptor interactions, to either a receptor-coated surface [33] or laterally mobile sialoglycolipid receptors embedded in a supported lipid bilayer [59]. Multivalent HA–receptor interactions, combined with NA activity, induced virus movement on a receptor-coated surface 32, 33, 60 until receptor density was decreased to an extent that allows virion elution [33]. Virus attached to sialoglycolipid receptors in a supported lipid biolayer were also shown to move by lateral diffusion of the attached sialoglycolipids in an NA-independent fashion [59]. Virion self-elution from a receptor-coated surface depended on the receptor-binding and -sialidase activity properties of HA and NA as well as on receptor density and identity 33, 34. The inferred speed of virus motility on a surface, and the self-elution rate, thus depend on the HA–NA–receptor balance governing the dynamics of virus–glycan interactions.

IAV cross-species transmission likely requires adjustment of the HA–NA–receptor balance as the sialoglycan repertoire differs between species 45, 46, 47, 48. Within the human host, changes in HA and NA activity resulting from antigenic drift may require functional coadaptation of HA and NA to restore the balance. This may be achieved by tuning the receptor (fine-)specificity and affinity of HA [61] and the activity of NA. Of note, all NA proteins preferentially cleave avian- over human-type receptors, although NA of human viruses cleaves human-type receptors relatively more efficiently 62, 63. One way to modulate NA activity is by mutation of the catalytic site which is, however, extremely conserved between avian and human viruses. Mutations in the active site are primarily observed upon development of resistance against NA inhibitors (NAIs) 64, 65, 66, 67. As an exception, recent human H3N2 viruses that depend on NA rather than HA for hemagglutination were recently shown to carry HA proteins with very weak receptor-binding properties and NA with presumed low activity due to a mutation in the catalytic site [68]. NA-dependent hemagglutination could also be observed upon passaging of H3N2 viruses on MDCK cells [69]. NA proteins with relatively low catalytic activity (low kcat) were recently shown by BLI to contribute to the virion–receptor binding rate 33, 57, which seems logical considering the relatively lower KD of NA than of HA for binding to sialosides [70].

NA carries a second SIA-binding site (2SBS) adjacent to the catalytic site (Figure 2) which is highly conserved in most avian, but not in (pandemic) human viruses 34, 63, 71, 72, 73. The 2SBS of different NA subtypes preferentially binds to avian-type receptors 34, 63, 74 and enhances cleavage of SIAs from multivalent receptor surfaces carrying these receptors. Binding via the 2SBS presumably enhances sialidase activity by bringing NA closer to its substrate, and is functionally reminiscent of the lectin-binding sites present in many glycosidases. The 2SBS may contribute to the virus–receptor binding rate in addition to HA 34, 57 and the active site of NAs with low catalytic activity 33, 57, 75. Altogether, this presents a range of options for fine-tuning the HA/NA/receptor balance that includes three receptor-binding sites (HA, and two on NA) and a cleavage site (NA), all organized in an oligomeric (trimeric HA, tetrameric NA) configuration (Figure 2). The loss of a functional 2SBS in the NA of human IAVs might have evolved as a functional prerequisite for restoring the functional balance in response to the new α2,6-linked human receptor repertoire that was encountered upon zoonotic transfer. Alternatively, the 2SBS may have lost its functional role in human IAVs and therefore have become apt to antigenic variation. Despite the general view that the primary change in adapting to a new host receptor repertoire takes place in HA, followed by further adaptations in NA, this is not the exclusive order of events. In the recently emerged H7N9 avian viruses mutation of the 2SBS, reducing binding to avian receptors, preceded the acquisition of the infamous Q226L mutation in HA which increased binding to human-type receptors [74]. Also in H9N2 avian viruses, mutation of the 2SBS is often found in company with the Q226L mutation in HA [76].

Additional mechanisms for tuning the HA–NA–receptor balance have been described. Changes in the length of the NA stalk domain usually (with some exceptions 77, 78) do not change the NA activity of a virus particle on soluble monomeric substrates or of the isolated NA protein. However, a shortened stalk affects virus replication in vivo and NA activity on multivalent substrates in the context of the viral particle in vitro 79, 80, thereby, for instance, reducing virus self-elution from erythrocytes. Steric hindrance by HA was suggested to limit access of a retracted NA head domain to SIA receptors on the cell surface [81]. Several reports have demonstrated that altered stalk length differentially affects replication in different hosts, emphasizing the importance of the HA–NA–receptor balance on host specificity 82, 83, 84. A shorter stalk is considered to be an adaptation of IAVs originating from the intestinal tract of waterfowl to the respiratory tract of chicken (reviewed in 85, 86). Also, virus particle morphology could have an impact on the HA–NA–receptor balance. In contrast to the mainly spherical morphology of laboratory-adapted IAVs harvested from in vitro cell cultures, clinical isolates often contain filamentous IAVs (reviewed in [87]) displaying an asymmetric surface distribution of HA and NA 60, 88, 89, 90 that may affect the HA–NA–receptor balance. Furthermore, mutations that affect intracellular transport and oligomerization of HA and NA 91, 92 could affect their ratio and distribution.

Getting in

Transmission of respiratory IAVs to a new host occurs by the airborne route via respiratory droplets or aerosols as well as by direct contact with mucosal secretions [93]. The site of primary infection (intranasal, tracheal, lung) may affect pathogenicity but, at all entry sites, it is inevitable that virus particles are rapidly deposited on the mucosal surface and bind to mucins densely covered with sialylated O-linked glycans (Figure 4). Inhibition of NA activity in the presence of mucus inhibits infection in vitro 43, 94, 95, 96 probably because, under these conditions, virus particles are not able to penetrate the mucus layer [97]. As outlined above, the HA–NA–receptor balance is critical for the interaction dynamics with an SIA receptor-coated surface. It is the NA activity that drives virus rolling/motility on such a receptor-coated substrate 32, 33 which needs to be sufficiently cleared of receptors by NA activity before the virus can dissociate [33]. Considering the presence of the enormous amount of SIA receptors on mucins (reviewed in [98]) relative to the small number of IAV particles required for starting an infection 99, 100, 101, we consider that dissociation of virus particles from the highly organized mucus structure is not likely. Instead, we and others 32, 33, 60 propose that NA activity will locally decrease the receptor density, and the resulting SIA gradient will drive virus movement to areas of higher concentration. The first microscopic studies on IAV motility have identified NA activity-driven directional motility of spherical IAV particles on fetuin-coated glass slides [32]. Crawling as well as gliding motility (movement over short and longer distances, respectively) were observed. Variation in length of alternating phases of strong and weak attachment of the virus particles, dependent on the HA–NA–receptor balance, were proposed to give rise to the two mechanisms of motion [32]. Others have studied the motility of filamentous IAVs (up to 1 μm in length) on fetuin-coated surfaces and in mucus gels [60]. Filamentous IAVs appeared to move with higher directionality than the spherical particles studied in [32] when NA displayed a polarized distribution, restricted to one pole, on the viral filaments. The NA-rich pole functioned as an outboard engine, propelling the filament forwards. Directionality was lost when NA was randomly distributed. Remarkably, filamentous influenza C virus (ICV) particles, which carry their receptor-binding site and receptor-destroying activity in a single hemagglutinin–esterase–fusion (HEF) protein also displayed highly directional motion on a mucus-coated substrate [102] which was less obvious for spherical ICV particles. Thus, receptor cleavage in combination with rapid receptor exchange on individual receptor-binding sites may be a general driving force for the motion of viruses belonging to different classes on different substrates as, for instance, also proposed for β-coronaviruses [103] which harbor a hemagglutinin esterase that evolved from ICV HEF. Given the observed directionality of movement on sialylated substrates, we hypothesize that mucins are not merely IAV decoy receptors but actually support rapid directional transfer of virus particles through a viscous mucus layer. Movement of particles through mucus will obviously depend on the HA–NA–receptor balance. Too strong binding by HA in combination with an NA with low sialidase activity has been shown to slow down the speed of virus rolling in vitro 32, 33, 34, while particle morphology and HA–NA distribution affect directionality 60, 102.

Upon crossing the viscous maze-like mucus layer, rich in soluble mucins, further penetration of a watery periciliary layer (PCL) is required in order to attach to sites on membranes of epithelial cells, resulting in endocytic entry. The PCL, from which soluble mucins are excluded, is formed by the cilia and microvilli that protrude from the membranes of ciliated cells, and the mucin-secreting goblet cells and serous cells, respectively [104]. These are the major cell types of the mammalian upper respiratory tract that face the mucus layer and of which at least ciliated and goblet cells can be infected by IAVs 105, 106, 107. The narrow space (<200 nm) in between the cilia, filled with a glycocalyx composed of sialylated membrane-tethered mucins and other glycoconjugates, is impenetrable for beads >40 nm by diffusion [108]. Thus, entry of >100 nm diameter IAV particles by endocytosis, which is likely to occur only at the base of these protrusions, requires the type of active transport that could be provided by NA activity-driven rolling over sialylated substrates and will be dependent on the HA–NA–receptor balance. It cannot be excluded that IAV primarily enters cells at regions where cilia density is less, for instance at cell–cell borders, but also in this case it is crucial that the relatively small number of particles that start a new infection do not become trapped in between cilia.

Once in close contact with the surface of the cell body, the virus needs to bind (enigmatic) functional receptors that allow/induce endocytic uptake. IAV entry has been shown to proceed by clathrin-mediated endocytosis (CME) as well as macropinocytosis (MP) (reviewed in [109]). Both entry routes fully depend on sialylated cell-surface receptors [110]. The latter was shown to require signaling by receptor tyrosine kinases (RTKs). Several different RTKs are involved, and their effects may be redundant as well as additive 110, 111. CME of IAVs does not follow the ubiquitous route of surfing into preformed clathrin-coated pits but is characterized by the de novo formation of a clathrin coat at sites where virus particles have become immobilized [112]. Such a process requires yet undefined, transmembrane signaling as well as fixation at a spot by stable binding to (clustered) receptors. Many eukaryotic signaling receptors are heavily decorated with (sialylated) N-linked glycans. N-linked glycans have been shown to be important, but not absolutely required, for IAV entry. Especially in cells lacking sialylated N-glycans, decoy receptors were shown to interfere with entry [38]. We speculate that weak binding to O-glycans on mucins may not only be needed to move through the mucus layer but also to allow transfer of virions to higher affinity receptors at the cell surface, which may be N-linked glycans in particular. Multiantennary N-linked glycans containing multiple LacNAc repeats were, by structural modeling, suggested to associate simultaneously with two receptor-binding sites (RBSs) in single HA trimers of H3N2 viruses isolated since the 1990s. The HA proteins of these viruses display high avidity for such glycans and do not bind to short LacNAc antennae as analyzed by glycan array analysis [21].

Of note, binding receptors and signaling receptors at entry spots supporting CME or MP are not necessarily the same entities, as multivalent IAV particles can engage multiple different receptors simultaneously. Viruses bind to cell surfaces displaying heterologous sialoglycan receptors, enabling hetero-multivalent virion–cell interactions that will affect the HA–NA–receptor balance and the dynamics of virus–receptor interactions in ways that have not been explored yet. Cell–cell interaction studies have shown that short-lived interactions can lead to signaling, and it has been suggested that these weak interactions can be enabled by higher affinity interactions involving receptors that do not signal 113, 114, 115. The same may hold true for weak interactions between virus and cell surface signaling receptors. Glycan arrays have so far mainly been employed for screening the binding of recombinant HA proteins. This approach focuses on identification of high-avidity binders whereas identification of low-affinity receptors necessarily relies on the highly multivalent binding mode of virions as used in BLI 33, 57, 58. Indeed the occasional use of virus particles on glycan arrays has shown its potential to identify a broader spectrum of receptors than by recombinant proteins 11, 13, 116. For instance, in contrast to the high specificity of recombinant HA of H7N9 for avian-type receptors [117], the corresponding H7N9 virus particles were shown to bind human- and avian-type receptors to similar levels [15]. Viruses could, in theory, move/roll in an HA–NA–receptor balance-dependent mode over the cell surface. However, this type of motility does not seem to be as crucial as that for penetrating the mucus layer as NA inhibitors have only a moderate effect on virus entry in vitro in a watery buffer of low protein content 38, 96. Possibly, under these conditions, IAV particles attach to abundantly present and highly mobile sialylated membrane protein receptors that surf with their cargo through the fluid lipid membrane over the cell surface. In the absence of NA activity, viruses do not roll 32, 33, but, because of the high KD of single HA–SIA interaction, we expect them to display NA activity-independent wobbling ‘on the spot’, which enables the virus particle to exchange bound receptors with closely adjoining receptors. Combined with surfing, such a mechanism may still allow the virus to recruit functional receptors required for entry.

Getting Out, and in Again

The crucial role for NA at the end of the infection cycle, when newly assembled particles at the cell surface are released from cells, has been abundantly documented. NA activity results in destruction of receptors that are otherwise bound by HA, both on the cell surface and on mucus. No release/aggregation of virus particles is observed when NA activity is blocked 35, 118, showing the crucial function of NA in producing infectious progeny. NA sialidase activity is probably not required at the site of particle assembly per se, but expression of NA rather results in a cell surface devoid of sialosides, which also prevents superinfection [119]. Subsequent spreading of an infection differs from a primary infection in particle numbers (much higher [120]) and location (directly at the epithelial cell surface) and may have a different requirement for the HA–NA–receptor balance. Particles that are assembled are often spherical, but those of clinical isolates may also be filamentous (reviewed in 87, 121). Very long filamentous particles are particularly easily observed when they are cell-associated ([121] and references therein), but may be more labile than spherical particles when released from cells [122]. The filamentous particle phenotype is lost upon passaging in vitro, mostly resulting from mutations in M1, while this phenotype is maintained or may even be regained upon passaging in vivo 87, 123, thereby suggesting an important, yet to be established, role for such particles in vivo. Filamentous particles may serve to efficiently spread from cell to cell when these cells are covered with a mucus layer. Alternatively, filamentous particles may be able to penetrate the mucus layer towards the luminal side and thereby be important for transmission. Of note, association of virus particles with mucus was shown to enhance particle stability in aerosols, and thereby transmissibility 124, 125. Likely, there is also an important role for the HA–NA–receptor balance in this respect, as, before infecting a new host, virus particles need to dissociate from these mucus molecules.

Concluding Remarks and Future Perspectives

Historically, identification of IAV receptors has mostly focused on the identification of receptors with high avidity for HA, despite the frequent demonstration of efficiently replicating IAVs that carry HAs with almost undetectable sialoglycan binding. At the same time, there has been a longstanding awareness of the requirement for an optimal HA–NA balance which, in simple terms, was defined as the need for matching HA affinities and NA activities in order to assure prevention of virions being trapped by decoy receptors but allowing binding to functional receptors on the cell surface. Only recently, the use of techniques that allow real-time detection of the dynamic interaction between IAV particles and receptor-coated surfaces, in the presence of NA activity, has permitted quantification of this balance. By multivalent interactions (avidity), HAs with low or relatively high binding affinity all support essentially irreversible virus binding to polyvalent receptor surfaces, as encountered in the mucus layer and on the cell surface, leading to the assumption that IAV particles are continuously in a receptor-bound state. It is the NA activity which, in conjunction with the KD of monomeric HA–receptor interactions, enables virus motility on such surfaces and thereby assures efficient penetration of the mucus layer and migration over the cell surface to an as yet undefined spot that permits (signaling-induced) virus entry. Further development of microscopy and BLI-based techniques should help to answer numerous questions that address the basic principles of the HA–NA–receptor balance and its role in IAV–receptor interaction dynamics.

Clearly, this balance needs to be addressed in respect of the highly heterogeneous receptor repertoire that is encountered within a host. The use of recombinant glycoproteins in BLI is a step forward, and recent developments in binding cells to BLI sensors [126] have opened opportunities to directly examine virus–cell interactions by this technique. This should provide a quantitative description of species-specific IAV–host balance in order to understand which adaptations are required for crossing the species barrier. While not only the cell surface but also the mucus layer likely poses a selective barrier 43, 127, their composition and interaction with IAV currently receives too little attention (see Outstanding Questions). Ultimately, studying the HA–NA–(decoy)receptor balance of viruses from different hosts, and the adjustment thereof by mutations in HA and NA, should have predictive value in linking naturally occurring amino acid substitutions to the potential of IAVs for altering their host range.

Outstanding Questions.

The HA–NA–receptor balance of distinct viruses adapted to different (as well as to the same) host species remains to be determined. In view of the plethora of (decoy) receptors that viruses encounter in vivo, it is not yet known which (combinations of) receptors are best suited to perform these analyses. In order to directly compare the HA–NA–balance of different viruses, the same receptors need to be used.

Is the functional HA–NA–receptor balance required for efficient replication in, and transmission between, specific host species a very narrow balance, or is the required balance not so strict?

It is not known whether the functional HA–NA–receptor balances of different viruses adapted to different host species are distinct or (partly) overlapping. Does an overlapping HA–NA–receptor balance window provide an increased opportunity for cross-species transmission?

Do IAVs need to bind to specific functional receptors on host cells to initiate infection? How large is the repertoire of functional receptors, and what is their redundancy?

To what extent does mucus from different host species differ in sialoglycan make-up, and to what extent does the mucus layer function as a host range barrier? Does mucus function as a barrier at all for a well-adapted virus, or may it even enhance virus infection by helping viruses to reach the underlying epithelial cells?

To what extent should we consider that IAV particles are continuously in a receptor-bound state in vivo when we study the ability of antibodies or molecules to interfere with HA or NA functions in vitro?

Glossary

Affinity

affinity indicates how tightly a ligand binds to a protein and is commonly described by the dissociation constant KD (the ligand concentration at which half of the protein-binding sites are occupied at equilibrium). We refer to affinity with respect to the interaction of a single HA protomer with a receptor.

Avidity

avidity refers to the accumulated strength of multiple individual binding interactions as they occur, for example, when a virion displaying multiple HA trimers interacts with a receptor-coated surface.

Biolayer interferometry (BLI)

a label-free technology, based on an optical analytical technique, for measuring biomolecular interactions on a biosensor surface.

Clathrin-mediated endocytosis (CME)

a process by which a cell internalizes extracellular components via inward budding of the plasma membrane. These inward buds are assembled with the help of clathrin molecules.

Glycan array

glycan arrays contain (synthetic) oligosaccharides immobilized on a solid support in a microarray format. They can be used for high-throughput analysis of protein–glycan interactions.

Macropinocytosis (MP)

an endocytosis process that results in the uptake of liquid material by cells from their external environment via heterogeneously sized intracellular vesicles called macropinosomes.

Multivalent binding

refers to binding between two entities via multiple binding sites (e.g., virus particle and cell surface/mucin).

N-linked glycan

an oligosaccharide attached to an asparagine residue of a protein. N-glycosylation is a cotranslational process that occurs in the endoplasmic reticulum. N-glycans are modified during transport of proteins along the secretory pathway. The final structure of N-linked glycans is determined by the protein and the cell in which it is expressed and varies across species.

O-linked glycan

O-linked glycosylation is the attachment of a sugar molecule to serine or threonine residues in a protein. O-glycosylation is a post-translational modification. After addition of the initial sugar, other sugars can be attached. In general, O-glycans are shorter and less complex than N-glycans. Mucins contain many O-glycans.

Receptor tyrosine kinases (RTKs)

transmembrane-containing tyrosine kinases that are cell-surface receptors for growth factors, cytokines, and hormones. Extracellular ligand binding will typically cause receptor di/oligomerization, which activates the receptor, thereby propagating a signal through the plasma membrane.

Sialic acid (SIA)

a nine-carbon saccharide that generally occupies a terminal position of an oligosaccharide (referred to as sialoglycan). SIAs are generally attached to a penultimate galactose via an α2,3- or an α2,6-linkage.

References

  • 1.Bouvier N.M., Palese P. The biology of influenza viruses. Vaccine. 2008;26(Suppl. 4):D49–D53. doi: 10.1016/j.vaccine.2008.07.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wu Y., et al. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 2014;22:183–191. doi: 10.1016/j.tim.2014.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rejmanek D., et al. Evolutionary dynamics and global diversity of influenza A virus. J. Virol. 2015;89:10993–11001. doi: 10.1128/JVI.01573-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Matrosovich M., et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J. Virol. 2000;74:8502–8512. doi: 10.1128/jvi.74.18.8502-8512.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rogers G.N., et al. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127:361–373. doi: 10.1016/0042-6822(83)90150-2. [DOI] [PubMed] [Google Scholar]
  • 6.Shi Y., et al. Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses. Nat. Rev. Microbiol. 2014;12:822–831. doi: 10.1038/nrmicro3362. [DOI] [PubMed] [Google Scholar]
  • 7.de Graaf M., Fouchier R.A. Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J. 2014;33:823–841. doi: 10.1002/embj.201387442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.de Vries R.P., et al. Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS Pathog. 2017;13:e1006390. doi: 10.1371/journal.ppat.1006390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gambaryan A., et al. Receptor specificity of influenza viruses from birds and mammals: new data on involvement of the inner fragments of the carbohydrate chain. Virology. 2005;334:276–283. doi: 10.1016/j.virol.2005.02.003. [DOI] [PubMed] [Google Scholar]
  • 10.Stevens J., et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006;312:404–410. doi: 10.1126/science.1124513. [DOI] [PubMed] [Google Scholar]
  • 11.Liu Y., et al. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J. Virol. 2010;84:12069–12074. doi: 10.1128/JVI.01639-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Childs R.A., et al. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat. Biotechnol. 2009;9:797–799. doi: 10.1038/nbt0909-797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gulati S., et al. Human H3N2 influenza viruses isolated from 1968 to 2012 show varying preference for receptor substructures with no apparent consequences for disease or spread. PLoS One. 2013;8:e66325. doi: 10.1371/journal.pone.0066325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Belser J.A., et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature. 2013;501:556–559. doi: 10.1038/nature12391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Watanabe T., et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501:551–555. doi: 10.1038/nature12392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Stevens J., et al. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J. Mol. Biol. 2008;381:1382–1394. doi: 10.1016/j.jmb.2008.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Peacock T.P., et al. Variability in H9N2 haemagglutininreceptor-binding preference and the pH of fusion. Emerg. Microbes Infect. 2017;6:e11. doi: 10.1038/emi.2016.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hensley S., et al. Receptor binding avidity drives influenza A virus antigenic drift. Science. 2009;326:734–736. doi: 10.1126/science.1178258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Koel B.F., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342:976–979. doi: 10.1126/science.1244730. [DOI] [PubMed] [Google Scholar]
  • 20.Koel B.F., et al. Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses. J. Virol. 2015;89:3763–3775. doi: 10.1128/JVI.02962-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Peng W., et al. Specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe. 2017;21:23–34. doi: 10.1016/j.chom.2016.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lin Y.P., et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 2012;109:21474–21579. doi: 10.1073/pnas.1218841110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wagner R., et al. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 2002;12:159–166. doi: 10.1002/rmv.352. [DOI] [PubMed] [Google Scholar]
  • 24.McAuley J.L., et al. Influenza virus neuraminidase structure and functions. Front. Microbiol. 2019;10:e00039. doi: 10.3389/fmicb.2019.00039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kosik I., Yewdell J.W. Influenza hemagglutinin and neuraminidase: Yin–Yang proteins coevolving to thwart immunity. Viruses. 2019;11:e346. doi: 10.3390/v11040346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gaymard A., et al. Functional balance between neuraminidase and haemagglutinin in influenza viruses. Clin. Microbiol. Infect. 2016;22:975–983. doi: 10.1016/j.cmi.2016.07.007. [DOI] [PubMed] [Google Scholar]
  • 27.Byrd-Leotis L., et al. The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase. Int. J. Mol. Sci. 2017;18:e1541. doi: 10.3390/ijms18071541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sauter N.K., et al. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry. 1989;28:8388–8396. doi: 10.1021/bi00447a018. [DOI] [PubMed] [Google Scholar]
  • 29.Takemoto D.K., et al. Surface plasmon resonance assay for the binding of influenza virus hemagglutinin to its sialic acid receptor. Virology. 1996;217:452–458. doi: 10.1006/viro.1996.0139. [DOI] [PubMed] [Google Scholar]
  • 30.Fei Y., et al. Characterization of receptor binding profiles of influenza A viruses using an ellipsometry-based label-free glycan microarray assay platform. Biomolecules. 2015;5:480–498. doi: 10.3390/biom5031480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Xiong X., et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature. 2018;497:392–396. doi: 10.1038/nature12144. [DOI] [PubMed] [Google Scholar]
  • 32.Sakai T., et al. Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. Sci. Rep. 2017;7:e45043. doi: 10.1038/srep45043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Guo H., et al. Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces. PLoS Pathog. 2018;14:e1007233. doi: 10.1371/journal.ppat.1007233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Du W., et al. The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance. PLoS Pathog. 2019;15:e1007860. doi: 10.1371/journal.ppat.1007860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Palese P., et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology. 1974;61:397–410. doi: 10.1016/0042-6822(74)90276-1. [DOI] [PubMed] [Google Scholar]
  • 36.Basak S., et al. Sialic acid is incorporated into influenza hemagglutinin glycoproteins in the absence of viral neuraminidase. Virus Res. 1985;2:61–68. doi: 10.1016/0168-1702(85)90060-7. [DOI] [PubMed] [Google Scholar]
  • 37.Chu V.C., et al. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2004;101:18153–18158. doi: 10.1073/pnas.0405172102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.de Vries E., et al. Influenza A virus entry into cells lacking sialylated N-glycans. Proc. Natl. Acad. Sci. U. S. A. 2012;109:7457–7462. doi: 10.1073/pnas.1200987109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Fujioka Y., et al. A sialylated voltage-dependent Ca(2+) channel binds hemagglutinin and mediates influenza A virus entry into mammalian cells. Cell Host Microbe. 2018;23:809–818. doi: 10.1016/j.chom.2018.04.015. [DOI] [PubMed] [Google Scholar]
  • 40.Leung H.S. Entry of influenza A virus with a α2,6-linked sialic acid binding preference requires host fibronectin. J. Virol. 2012;86:10704–10713. doi: 10.1128/JVI.01166-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Vrijens P. Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor-signalling pathway. J. Gen. Virol. 2019;100:583–601. doi: 10.1099/jgv.0.001235. [DOI] [PubMed] [Google Scholar]
  • 42.Kesimer M., et al. Unpacking a gel-forming mucin: a view of MUC5B organization after granular release. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010;298:L15–L22. doi: 10.1152/ajplung.00194.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Zanin M., et al. The interaction between respiratory pathogens and mucus. Cell Host Microbe. 2016;19:159–168. doi: 10.1016/j.chom.2016.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kesimer M., et al. Physical characterization and profiling of airway epithelial derived exosomes using light scattering. Methods. 2015;87:59–63. doi: 10.1016/j.ymeth.2015.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Lakdawala S.S., et al. The soft palate is an important site of adaptation for transmissible influenza viruses. Nature. 2015;526:122–125. doi: 10.1038/nature15379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Jia N., et al. Glycomic characterization of respiratory tract tissues of ferrets: implications for its use in influenza virus infection studies. J. Biol. Chem. 2014;289:28489–28504. doi: 10.1074/jbc.M114.588541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Chan R.W., et al. Infection of swine ex vivo tissues with avian viruses including H7N9 and correlation with glycomic analysis. Influ. Other Respir. Viruses. 2013;6:1269–1282. doi: 10.1111/irv.12144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Walther T., et al. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog. 2013;9:e1003223. doi: 10.1371/journal.ppat.1003223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rogers G.N., et al. Differential sensitivity of human, avian, and equine influenza A viruses to a glycoprotein inhibitor of infection: selection of receptor specific variants. Virology. 1983;131:394–408. doi: 10.1016/0042-6822(83)90507-x. [DOI] [PubMed] [Google Scholar]
  • 50.Kaverin N.V., et al. Post-reassortment changes in influenza A virus hemagglutinin restoring HA-NA functional match. Virology. 1998;244:315–321. doi: 10.1006/viro.1998.9119. [DOI] [PubMed] [Google Scholar]
  • 51.Kaverin N.V., et al. Intergenic HA–NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes. Virus Res. 2000;66:123–129. doi: 10.1016/s0168-1702(99)00131-8. [DOI] [PubMed] [Google Scholar]
  • 52.Mitnaul L.J., et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J. Virol. 2000;74:6015–6020. doi: 10.1128/jvi.74.13.6015-6020.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hughes M.T., et al. Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity. J. Virol. 2001;75:3766–3770. doi: 10.1128/JVI.75.8.3766-3770.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hughes M.T., et al. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J. Virol. 2000;74:5206–5212. doi: 10.1128/jvi.74.11.5206-5212.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Xu R., et al. Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J. Virol. 2012;86:9221–9232. doi: 10.1128/JVI.00697-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Xiong X., et al. Enhanced human receptor binding by H5 haemagglutinins. Virology. 2014;457:179–187. doi: 10.1016/j.virol.2014.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Benton D.J., et al. Role of neuraminidase in influenza A(H7N9) virus receptor binding. J. Virol. 2017;91 doi: 10.1128/JVI.02293-16. e02293–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Benton D.J., et al. Biophysical measurement of the balance of influenza a hemagglutinin and neuraminidase activities. J. Biol. Chem. 2015;290:6516–6521. doi: 10.1074/jbc.M114.622308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Müller M., et al. Mobility-based quantification of multivalent virus-receptor interactions: new insights into influenza a virus binding mode. Nano Lett. 2019;19:1875–1882. doi: 10.1021/acs.nanolett.8b04969. [DOI] [PubMed] [Google Scholar]
  • 60.Vahey M.D., Fletcher D.A. Influenza A virus surface proteins are organized to help penetrate host mucus. eLife. 2019;8:e43764. doi: 10.7554/eLife.43764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Ji Y., et al. New insights into influenza A specificity: an evolution of paradigms. Curr. Opin. Struct. Biol. 2017;44:219–231. doi: 10.1016/j.sbi.2017.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Baum L.G., Paulson J.C. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology. 1991;180:10–15. doi: 10.1016/0042-6822(91)90003-t. [DOI] [PubMed] [Google Scholar]
  • 63.Du W., et al. Substrate binding by the second sialic acid-binding site of influenza A virus N1 neuraminidase contributes to enzymatic activity. J. Virol. 2018;92 doi: 10.1128/JVI.01243-18. e01243-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Gulati S., et al. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virol. J. 2009;22:e1743. doi: 10.1186/1743-422X-6-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Eshaghi A., et al. Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient. Antimicrob. Agents Chemother. 2015;58:7188–7197. doi: 10.1128/AAC.03667-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Tamura D., et al. Emergence of multidrug-resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir. J. Infect. Dis. 2015;212:1209–1213. doi: 10.1093/infdis/jiv245. [DOI] [PubMed] [Google Scholar]
  • 67.van der Vries E. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 2010;363:1381–1382. doi: 10.1056/NEJMc1003749. [DOI] [PubMed] [Google Scholar]
  • 68.Mögling R., et al. Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site. J. Gen. Virol. 2017;98:1274–1281. doi: 10.1099/jgv.0.000809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Mohr P.G., et al. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virol. J. 2015;67:s12985. doi: 10.1186/s12985-015-0295-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Reiter-Scherer V., et al. Force spectroscopy shows dynamic binding of influenza hemagglutinin and neuraminidase to sialic acid. Biophys. J. 2019;116:1037–1048. doi: 10.1016/j.bpj.2019.01.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Sung J.C., et al. Role of secondary sialic acid binding sites in influenza N1 neuraminidase. J. Am. Chem. Soc. 2010;132:2883–2885. doi: 10.1021/ja9073672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Varghese J.N., et al. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc. Natl. Acad. Sci. U. S. A. 1997;94:11808–11812. doi: 10.1073/pnas.94.22.11808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Uhlendorff J., et al. Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch. Virol. 2009;154:945–957. doi: 10.1007/s00705-009-0393-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Dai M., et al. Mutation of the second sialic acid-binding site, resulting in reduced neuraminidase activity, preceded the emergence of H7N9 influenza A virus. J. Virol. 2017;91:e00049. doi: 10.1128/JVI.00049-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Hiono T., et al. Amino acid residues at positions 222 and 227 of the hemagglutinin together with the neuraminidase determine binding of H5 avian influenza viruses to sialyl Lewis X. Arch. Virol. 2016;161:307–316. doi: 10.1007/s00705-015-2660-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Matrosovich M.N., et al. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology. 2001;281:156–162. doi: 10.1006/viro.2000.0799. [DOI] [PubMed] [Google Scholar]
  • 77.Durrant J.D., et al. Microsecond molecular dynamics simulations of influenza neuraminidase suggest a mechanism for the increased virulence of stalk-deletion mutants. J. Phys. Chem. B. 2016;120:8590–8599. doi: 10.1021/acs.jpcb.6b02655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Zanin M., et al. An amino acid in the stalk domain of N1 neuraminidase is critical for enzymatic activity. J. Virol. 2017;91:e00868–e00916. doi: 10.1128/JVI.00868-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Els M.C., et al. An 18-amino acid deletion in an influenza neuraminidase. Virology. 1985;142:241–247. doi: 10.1016/0042-6822(85)90332-0. [DOI] [PubMed] [Google Scholar]
  • 80.Castrucci M.R., Kawaoka Y. Biologic importance of neuraminidase stalk length in influenza A virus. J. Virol. 1993;67:759–764. doi: 10.1128/jvi.67.2.759-764.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Baigent S.J., McCauley J.W. Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 2001;79:177–185. doi: 10.1016/s0168-1702(01)00272-6. [DOI] [PubMed] [Google Scholar]
  • 82.Matsuoka Y., et al. Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J. Virol. 2009;83:4704–4708. doi: 10.1128/JVI.01987-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Blumenkrantz D., et al. The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. J. Virol. 2013;87:10539–10551. doi: 10.1128/JVI.00967-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Hoffmann T.W., et al. Length variations in the NA stalk of an H7N1 influenza virus have opposite effects on viral excretion in chickens and ducks. J. Virol. 2012;86:584–588. doi: 10.1128/JVI.05474-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Long J.S., et al. One-way trip: influenza virus’ adaptation to gallinaceous poultry may limit its pandemic potential. Bioessays. 2015;37:204–212. doi: 10.1002/bies.201400133. [DOI] [PubMed] [Google Scholar]
  • 86.Li J., et al. Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses. PLoS One. 2011;6:e14722. doi: 10.1371/journal.pone.0014722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Badham M.D., Rossman J.S. Filamentous influenza viruses. Curr. Clin. Microbiol. Rep. 2016;3:155–161. doi: 10.1007/s40588-016-0041-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Harris A., et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl Acad. Sci. U. S. A. 2006;103:19123–19127. doi: 10.1073/pnas.0607614103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Calder L.J., et al. Structural organization of a filamentous influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2010;107:10685–10690. doi: 10.1073/pnas.1002123107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Rossman J.S., Lamb R.A. Influenza virus assembly and budding. Virology. 2011;411:229–236. doi: 10.1016/j.virol.2010.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Hensley S.E. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One. 2011;6:e15190. doi: 10.1371/journal.pone.0015190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Das S.R. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe. 2013;13:314–323. doi: 10.1016/j.chom.2013.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Kutter J.S., et al. Transmission routes of respiratory viruses among humans. Curr. Opin. Virol. 2018;28:142–151. doi: 10.1016/j.coviro.2018.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Matrosovich M.N., et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004;78:12665–12667. doi: 10.1128/JVI.78.22.12665-12667.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Cohen M., et al. Notable aspects of glycan–protein interactions. Biomolecules. 2015;5:2056–2072. doi: 10.3390/biom5032056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Cohen M., et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 2013;10:321. doi: 10.1186/1743-422X-10-321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Yang X., et al. A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One. 2014;9:e110026. doi: 10.1371/journal.pone.0110026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Duncan G.A., et al. The mucus barrier to inhaled gene therapy. Mol. Ther. 2016;24:2043–2053. doi: 10.1038/mt.2016.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Varble A., et al. Influenza A virus transmission bottlenecks are defined by infection route and recipient host. Cell Host Microbe. 2014;16:691–700. doi: 10.1016/j.chom.2014.09.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Poon L.L., et al. Quantifying influenza virus diversity and transmission in humans. Nat. Genet. 2016;48:195–200. doi: 10.1038/ng.3479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Sobel Leonard A., et al. Transmission bottleneck size estimation from pathogen deep- sequencing data, with an application to human influenza a virus. J. Virol. 2017;91 doi: 10.1128/JVI.00171-17. e00171–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Sakai T., et al. Unique directional motility of influenza C virus controlled by its filamentous morphology and short-range motions. J. Virol. 2018;92 doi: 10.1128/JVI.01522-17. e01522-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Tortorici M.A., et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 2019;26:481–489. doi: 10.1038/s41594-019-0233-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Bals R. Cell types of respiratory epithelium: morphology, molecular biology and clinical significance. Pneumologie. 1997;51:142–149. [PubMed] [Google Scholar]
  • 105.Ibricevic A., et al. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J. Virol. 2006;80:7469–7480. doi: 10.1128/JVI.02677-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Davis A.S., et al. Validation of normal human bronchial epithelial cells as a model for influenza A infections in human distal trachea. J. Histochem. Cytochem. 2015;63:312–328. doi: 10.1369/0022155415570968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Chan R.W., et al. Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses. Virus Res. 2013;178:133–145. doi: 10.1016/j.virusres.2013.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Button B., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science. 2012;337:937–941. doi: 10.1126/science.1223012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Edinger T.O., et al. Entry of influenza A virus: host factors and antiviral targets. J. Gen. Virol. 2014;95:263–277. doi: 10.1099/vir.0.059477-0. [DOI] [PubMed] [Google Scholar]
  • 110.de Vries E., et al. Dissection of the influenza A virus endocytic routes reveals macropinocytosis as an alternative entry pathway. PLoS Pathog. 2011;7:e1001329. doi: 10.1371/journal.ppat.1001329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Eierhoff T., et al. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells. PLoS Pathog. 2010;6:e1001099. doi: 10.1371/journal.ppat.1001099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Rust M.J., et al. Assembly of endocytic machinery around individual influenza viruses during viral entry. Nat. Struct. Mol. Biol. 2004;11:567–573. doi: 10.1038/nsmb769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Davis S.J., et al. The role of charged residues mediating low affinity protein–protein recognition at the cell surface by CD2. Proc. Natl Acad. Sci. U. S. A. 1998;95:5490–5494. doi: 10.1073/pnas.95.10.5490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Wright G.J. Signal initiation in biological systems: the properties and detection of transient extracellular protein interactions. Mol. Biosyst. 2009;5:1405–1412. doi: 10.1039/b903580j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Lever M., et al. Phenotypic models of T cell activation. Nat. Rev. Immunol. 2014;14:619–629. doi: 10.1038/nri3728. [DOI] [PubMed] [Google Scholar]
  • 116.Gulati S., et al. Glycan array analysis of influenza H1N1 binding and release. Cancer Biomark. 2014;14:43–53. doi: 10.3233/CBM-130376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Xu R., et al. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science. 2013;342:1230–1235. doi: 10.1126/science.1243761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Hinshaw V.S., et al. Altered tissue tropism of human-avian reassortant influenza viruses. Virology. 1983;128:260–263. doi: 10.1016/0042-6822(83)90337-9. [DOI] [PubMed] [Google Scholar]
  • 119.Huang I.C. Influenza A virus neuraminidase limits viral superinfection. J. Virol. 2008;82:4834–4843. doi: 10.1128/JVI.00079-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Jacobs N.T. Incomplete influenza A virus genomes occur frequently but are readily complemented during localized viral spread. Nat. Commun. 2019;10:3526. doi: 10.1038/s41467-019-11428-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Dadonaite B., et al. Filamentous influenza viruses. J. Gen. Virol. 2016;97:1755–1764. doi: 10.1099/jgv.0.000535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Rossman J.S., et al. Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J. Virol. 2010;84:5078–8508. doi: 10.1128/JVI.00119-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Seladi-Schulman J., et al. Spherical influenza viruses have a fitness advantage in embryonated eggs, while filament-producing strains are selected in vivo. J. Virol. 2013;87:13343–13353. doi: 10.1128/JVI.02004-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Kormuth K.A., et al. Influenza virus infectivity is retained in aerosols and droplets independent of relative humidity. J. Infect. Dis. 2018;218:739–747. doi: 10.1093/infdis/jiy221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Thomas Y., et al. Survival of influenza virus on banknotes. Appl. Environ. Microbiol. 2008;74:3002–3007. doi: 10.1128/AEM.00076-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Verzijl D., et al. A novel label-free cell-based assay technology using biolayer interferometry. Biosens. Bioelectron. 2017;87:388–395. doi: 10.1016/j.bios.2016.08.095. [DOI] [PubMed] [Google Scholar]
  • 127.Zanin M., et al. Pandemic swine H1N1 Influenza viruses with almost undetectable neuraminidase activity are not transmitted via aerosols in ferrets and are inhibited by human mucus but not swine mucus. J. Virol. 2015;89:5935–5948. doi: 10.1128/JVI.02537-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Wasilewski S., et al. Distribution of surface glycoproteins on influenza A virus determined by electron cryotomography. Vaccine. 2012;30:7368–7373. doi: 10.1016/j.vaccine.2012.09.082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Wu N.C., et al. A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. Nat. Commun. 2018;9:1264. doi: 10.1038/s41467-018-03663-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Vavricka C.J., et al. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat. Commun. 2013;4:1491. doi: 10.1038/ncomms2487. [DOI] [PubMed] [Google Scholar]

Articles from Trends in Microbiology are provided here courtesy of Elsevier

RESOURCES